Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Overview of attention for article published in The Lancet, July 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 10 news outlets
policy: 3 policy sources
twitter: 32 X users
patent: 3 patents

facebook: 3 Facebook pages
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 535 Mendeley

So far, Altmetric has seen 33 X posts from 32 X users, with an upper bound of 930,494 followers.

Open Access UCL Research: Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/dMKBOhRQFX

RT @Matt_Muscle_Guy: 8. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, doubl…

8. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. https://t.co/2QxU8B0Q4E

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 29 additional X posts.